Sichuan Baili Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS88
PHASE 3 / 2-334
RECRUITING45
READOUTS ≤12 MONTHS37
READOUT SLIPPED >6 MO54%
Delay Index: of 59 active trials registered more than a year ago, 32 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.0 months). See all sponsors →
Open Sichuan Baili Pharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| BL-M07D1 NCT06445400 |
P2 | Active, not recruiting | HER2-positive Breast Cancer | 83 | 2025-07-21 (-10 mo) |
| BL-B01D1 NCT06304974 |
P3 | Active, not recruiting | Esophageal Squamous Cell Carcinoma | 497 | 2025-10-17 (-6 mo) |
| SI-B001 NCT05044897 |
P2 | Active, not recruiting | Head and Neck Squamous Cell Carcinoma | 11 | 2025-12 (+29 mo) |
| GNC-038 NCT05485753 |
P1/2 | Active, not recruiting | Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma | 7 | 2025-12 (+7 mo) |
| SI-B001 NCT05022654 |
P2 | Active, not recruiting | Esophageal Squamous Cell Carcinomas | 22 | 2025-12 (+27 mo) |
| GNC-038 NCT05192486 |
P1/2 | Active, not recruiting | Diffuse Large B-cell Lymphoma | 12 | 2025-12 (+24 mo) |
| BL-M02D1 NCT05949619 |
P1/2 | Active, not recruiting | Non-small Cell Lung Cancer | 14 | 2025-12 (+4 mo) |
| GNC-038 NCT05627856 |
P1/2 | Active, not recruiting | NK/T Cell Lymphoma; Vascular Immunomother T Cell Lymphoma | 4 | 2025-12 (+13 mo) |
| SI-B001 NCT05020457 |
P2 | Active, not recruiting | Non Small Cell Lung Cancer | 69 | 2025-12 (+26 mo) |
| GNC-035 NCT05944978 |
P1/2 | Active, not recruiting | Relapsed/Refractory Chronic Lymphocytic Leukemia | 3 | 2025-12 (+4 mo) |
| SI-B001 NCT05020769 |
P2/3 | Active, not recruiting | Non-small Cell Lung Cancer | 14 | 2025-12 (+26 mo) |
| BL-B01D1 NCT06382142 |
P3 | Active, not recruiting | Triple-Negative Breast Cancer | 418 | 2026-01-13 (-4 mo) |
| SI-B001 NCT05943795 |
P3 | Active, not recruiting | Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung | 589 | 2026-07 |
| BL-B01D1 NCT06382116 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 432 | 2026-08 (+3 mo) |
| BL-B01D1 NCT06343948 |
P3 | Active, not recruiting | HR+HER2- Breast Cancer | 383 | 2026-08 (+3 mo) |
| BL-M07D1 NCT06316531 |
P3 | Active, not recruiting | HER2-positive Breast Cancer | 274 | 2026-10 (+5 mo) |
| BL-M07D1 NCT06423885 |
P2 | Active, not recruiting | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | 64 | 2026-10 (+4 mo) |
| BL-B01D1 for Injection NCT06598787 |
P2 | Recruiting | Recurrent Glioblastoma | 20 | 2026-10 |
| SI-B001 NCT06668961 |
P2 | Active, not recruiting | Head and Neck Squamous Cell Carcinoma | 48 | 2026-11 |
| BL-B01D1 NCT06118333 |
P3 | Active, not recruiting | Nasopharyngeal Carcinoma | 386 | 2026-11 (+11 mo) |
| SI-B001 NCT05668858 |
P1/2 | Active, not recruiting | Squamous Cell Carcinoma of Head and Neck | 70 | 2026-12 (+24 mo) |
| BL-M07D1 NCT06031584 |
P1/2 | Recruiting | Her2-positive/Low-expression Urinary and Digestive Tract Tumors | 42 | 2026-12 (+13 mo) |
| SI-B001 NCT05949606 |
P1/2 | Active, not recruiting | Non-small Cell Lung Cancer | 95 | 2026-12 (+16 mo) |
| BL-B01D1 NCT06405425 |
P2 | Recruiting | Urothelial Carcinoma | 52 | 2026-12 (+7 mo) |
| BL-B01D1 NCT06500026 |
P3 | Active, not recruiting | Small Cell Lung Cancer | 722 | 2026-12 (+5 mo) |
| GNC-038 NCT05623982 |
P1/2 | Recruiting | Non-hodgkin's Lymphoma | 40 | 2026-12 (+28 mo) |
| BL-B01D1 NCT06471205 |
P2 | Recruiting | Triple-negative Breast Cancer | 52 | 2026-12 (+5 mo) |
| BL-B01D1 NCT06382129 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 698 | 2026-12 (+7 mo) |
| BL-B01D1 NCT06006169 |
P2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 186 | 2026-12 (+15 mo) |
| SI-B001 NCT05054439 |
P2 | Active, not recruiting | Head and Neck Squamous Cell Carcinoma | 45 | 2026-12 (+41 mo) |
| BL-B01D1 NCT05956587 |
P2 | Recruiting | Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma | 121 | 2026-12 (+16 mo) |
| BL-B01D1 NCT06437509 |
P2 | Recruiting | Extensive-stage Small-cell Lung Cancer | 66 | 2026-12 (+6 mo) |
| BL-B01D1 NCT05803018 |
P1/2 | Recruiting | Gynecological Malignant Tumor; Solid Tumor | 38 | 2026-12 (+43 mo) |
| GNC-035 NCT06066203 |
P1/2 | Recruiting | Non-hodgkin's Lymphoma | 40 | 2026-12 (+13 mo) |
| SI-B003 NCT06008054 |
P2 | Recruiting | Esophageal Cancer; Gastric Cancer | 376 | 2026-12 (+15 mo) |
| BL-B01D1 NCT05785039 |
P2 | Recruiting | Urinary System Tumor; Solid Tumor | 76 | 2026-12 (+20 mo) |
| BL-B01D1 NCT05965856 |
P2 | Recruiting | Urothelial Carcinoma; Solid Tumor | 52 | 2026-12 (+16 mo) |
| BL-B01D1 NCT06042894 |
P2 | Recruiting | Breast Cancer | 58 | 2026-12 (+13 mo) |
| BL-M07D1 NCT06114511 |
P1/2 | Active, not recruiting | Non-small Cell Lung Cancer | 78 | 2026-12 (+12 mo) |
| BL-B01D1 NCT05924841 |
P2 | Recruiting | Small Cell Lung Cancer | 100 | 2026-12 (+17 mo) |
| BL-B01D1 NCT05990803 |
P2 | Recruiting | Cervical Cancer | 130 | 2026-12 (+15 mo) |
| BL-M07D1 NCT06131450 |
P1/2 | Recruiting | Gynecological Malignancies | 158 | 2027-01 (+13 mo) |
| BL-B01D1 NCT06978114 |
P2 | Recruiting | Advanced Biliary Tract Cancer | 46 | 2027-05 |
| BL-B01D1 NCT06986785 |
P2 | Recruiting | Advanced Hepatocellular Carcinoma | 74 | 2027-05 |
| BL-M07D1 NCT06957886 |
P3 | Recruiting | HER2-low Breast Cancer | 566 | 2027-05 |
| BL-B01D1 NCT07054567 |
P2 | Recruiting | Cervical Cancer; Endometrial Cancer | 96 | 2027-05 |
| BL-B01D1 NCT06962787 |
P2 | Recruiting | Renal Cancer | 260 | 2027-05 |
| BL-B01D1 NCT06857175 |
P3 | Active, not recruiting | Urothelial Carcinoma | 515 | 2027-06 |
| BL-B01D1 NCT06475300 |
P2 | Recruiting | Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma | 570 | 2027-06 (+11 mo) |
| BL-B01D1 NCT06994195 |
P3 | Recruiting | Epithelial Ovarian Cancer; Fallopian Tube Cancer | 450 | 2027-06 |
| BL-B01D1 NCT06787664 |
P2 | Active, not recruiting | Chordoma | 27 | 2027-06 |
| BL-M07D1 NCT07152405 |
P3 | Recruiting | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | 490 | 2027-06 |
| BL-B01D1 NCT06498986 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 76 | 2027-06 (+10 mo) |
| BL-B01D1 NCT06437522 |
P2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 46 | 2027-06 (+12 mo) |
| BL-B01D1 NCT05880706 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 198 | 2027-07 (+24 mo) |
| BL-M07D1 NCT07730489 |
P3 | Not yet recruiting | Colorectal Cancer | 130 | 2027-12 |
| BL-M07D1 NCT07264816 |
P2 | Recruiting | Non-squamous Non-small Cell Lung Cancer | 80 | 2027-12 |
| BL-M11D1 NCT07255872 |
P2/3 | Recruiting | Acute Myeloid Leukemia | 216 | 2027-12 |
| BL-M07D1 NCT07178795 |
P3 | Recruiting | Non-squamous Non-small Cell Lung Cancer | 440 | 2027-12 |
| BL-B01D1 NCT07827261 |
P2 | Not yet recruiting | Non-small Cell Lung Cancer | 36 | 2028-12 |
| BL-M07D1 NCT06891833 |
P2/3 | Recruiting | HER2-positive Breast Cancer | 985 | 2028-12 |
| BL-M08D1 NCT07780318 |
P1/2 | Recruiting | Gastrointestinal Tumors; Solid Tumors | 60 | 2028-12 |
| BL-M09D1 NCT07769229 |
P2 | Not yet recruiting | Gynecological Malignancies; Solid Tumors | 126 | 2028-12 |
| BL-M08D1 NCT07818499 |
P1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 204 | 2028-12 |
| BL-B01D1 NCT07641855 |
P2/3 | Not yet recruiting | Castration-resistant Prostate Cancer | 180 | 2028-12 |
| BL-B01D1 NCT07648914 |
P3 | Recruiting | Breast Cancer | 446 | 2028-12 |
| BL-B01D1 NCT07554456 |
P2/3 | Recruiting | Esophageal Squamous Cell Carcinoma | 90 | 2028-12 |
| BL-B01D1 NCT07582315 |
P3 | Recruiting | Biliary Tract Cancer | 538 | 2028-12 |
| BL-M07D1 NCT07678957 |
P2 | Recruiting | Breast Cancer | 120 | 2028-12 |
| BL-M07D1 NCT07545460 |
P3 | Not yet recruiting | Epithelial Ovarian Cancer; Fallopian Tube Cancer | 404 | 2028-12 |
| BL-M08D1 NCT07841925 |
P1/2 | Recruiting | Melanoma; Solid Tumors | 30 | 2028-12 |
| BL-M07D1 NCT07606599 |
P3 | Recruiting | Biliary Tract Cancer | 398 | 2028-12 |
| BL-M08D1 NCT07818486 |
P1/2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC); Solid Tumors | 30 | 2028-12 |
| BL-M08D1 NCT07793825 |
P1/2 | Not yet recruiting | Gynecological Tumors; Solid Tumors | 90 | 2028-12 |
| BL-B01D1 NCT06838273 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 724 | 2028-12 |
| BL-M09D1 NCT07837622 |
P2 | Not yet recruiting | Urothelial Carcinoma (UC); Solid Tumors | 42 | 2028-12 |
| BL-M11D1 NCT07591168 |
P1/2 | Not yet recruiting | Myelodysplastic Syndromes | 92 | 2028-12 |
| BL-M08D1 NCT07788950 |
P2 | Not yet recruiting | Head and Neck Squamous Cell Carcinomas; Solid Tumors | 30 | 2028-12 |
| BL-M07D1 NCT07518173 |
P3 | Recruiting | HER2-positive Breast Cancer | 596 | 2029-12 |
| BL-B01D1 NCT07739199 |
P2/3 | Recruiting | Squamous Non-small-cell Lung Cancer | 326 | 2029-12 |
| BL-B01D1 NCT07502300 |
P3 | Recruiting | Extensive-stage Small-cell Lung Cancer | 562 | 2029-12 |
| BL-B01D1 NCT07729956 |
P3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 436 | 2029-12 |
| BL-B01D1 NCT07739186 |
P2/3 | Recruiting | Non-squamous Non-small Cell Lung Cancer | 166 | 2029-12 |
| BL-B01D1 NCT07640789 |
P3 | Recruiting | Non-small Cell Lung Cancer Stage III | 418 | 2030-12 |
| BL-B01D1 NCT07797881 |
P2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 60 | 2030-12 |
| BL-M07D1 NCT06830889 |
P3 | Recruiting | HER2-positive Breast Cancer | 1450 | 2031-10 |
| BL-B01D1 NCT07642024 |
P2/3 | Recruiting | Non-small Cell Lung Cancer | 90 | 2032-12 |
| BL-B01D1 NCT07783321 |
P3 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 404 | 2033-12 |